According to global cancer data, lung cancer was the leading cause of cancer‑related death
in 2020. With the diversification of treatment strategies, the survival outcomes of patients with …

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) are
standard of care in the first-line (1L) setting for patients with metastatic non–small cell lung …

EGFR inhibitors (EGFRi) are standard-of-care treatments administered to patients with non–
small cell lung cancer (NSCLC) that harbor EGFR alterations. However, development of …

Multiple oncogenic molecular alterations have been discovered that serve as potential drug
targets in non-small cell lung cancer (NSCLC). While the pathogenic and pharmacological …

Background: Epidermal growth factor receptor-mutated (EGFR+) non-small-cell lung cancer
(NSCLC) patients failing tyrosine kinase inhibitors (TKI) can benefit from next-line targeted …

Non-small cell lung cancer (NSCLC) has historically been associated with a poor prognosis
and low 5-year survival, but the use of targeted therapies in NSCLC has improved patient …

Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are
standard of care for EGFR mutation-positive non-small cell lung cancer (NSCLC). However …

Few data are available that have compared outcomes with different EGFR tyrosine kinase
inhibitors (TKIs) specifically in Asian patients with EGFR mutation-positive non-small-cell …

Purpose Mesenchymal–epithelial transition (MET) amplification is one of the mechanisms
accounting for the resistance of epidermal growth factor receptor (EGFR) tyrosine kinase …

Background: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are
standard treatments for advanced EGFR-mutated non–small cell lung cancer (NSCLC) …